SP1 and cancer: Based on these findings we propose the model shown in Fig. 6F where ACTL6A interacts at the p53 and Sp1 transcription factor binding sites to interfere with positive transcriptional regulators (such as p53) to reduce p21Cip1 promoter expression and enhance the cancer phenotype.